Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Mallinckrodt
Baxter
Harvard Business School
Johnson and Johnson

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Arhalofenate

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Arhalofenate?

Arhalofenate is an investigational drug.

There have been 5 clinical trials for Arhalofenate. The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2011.

The most common disease conditions in clinical trials are Gout, Hyperuricemia, and [disabled in preview]. The leading clinical trial sponsors are CymaBay Therapeutics, Inc. and [disabled in preview].

There are eight US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Arhalofenate
TitleSponsorPhase
Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With GoutCymaBay Therapeutics, Inc.Phase 2
Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout PatientsCymaBay Therapeutics, Inc.Phase 2
Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout PatientsCymaBay Therapeutics, Inc.Phase 2

See all Arhalofenate clinical trials

Clinical Trial Summary for Arhalofenate

Top disease conditions for Arhalofenate
Top clinical trial sponsors for Arhalofenate

See all Arhalofenate clinical trials

US Patents for Arhalofenate

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Arhalofenate   Start Trial Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent CymaBay Therapeutics, Inc. (Newark, CA) DiaTex, Inc. (San Antonio, TX)   Start Trial
Arhalofenate   Start Trial Process for the preparation of (-)-(4-chloro-phenyl)-(3-trifluoromethyl-phenoxy)-acetic acid 2-acetylamino-ethyl ester Metabolex, Inc. (Hayward, CA)   Start Trial
Arhalofenate   Start Trial DCC mediated coupling for halofenate manufacture Cymabay Therapeutics, Inc. (Newark, CA)   Start Trial
Arhalofenate   Start Trial Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent Cymabay Therapeutics, Inc. (Newark, CA)   Start Trial
Arhalofenate   Start Trial Methods for treating gout flares CYMABAY THERAPEUTICS, INC. (Newark, CA)   Start Trial
Arhalofenate   Start Trial Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent CymaBay Therapeutics, Inc. (Newark, CA) DiaTex, Inc. (San Antonio, TX)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Medtronic
Baxter
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.